Logo Image

Ataxia

Latest News

February 28th 2023
FDA Approves Omaveloxolone As First Treatment for Friedreich Ataxia

The Reata Pharmaceuticals therapy, branded as Skyclarys, is indicated for adults and adolescents aged 16 years and older.

CME Content

View More
Increasing Awareness of Therapeutic Options for Thymidine Kinase 2 Deficiency (TK2d)
Video

Increasing Awareness of Therapeutic Options for Thymidine Kinase 2 Deficiency (TK2d)

Michio Hirano, MD; Mary Kay Koenig, MD; Zarazuela Zolkipli-Cunningham, MBChB, MRCP

View more
Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis
Video

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Abigail Schwaede, MD; Alexis Lizarraga, MD, MS

View more
Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis
Video

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

View more
How Do I Identify MOGAD? Improving Outcomes Through Early Identification of Patients
Video

How Do I Identify MOGAD? Improving Outcomes Through Early Identification of Patients

Michael Levy, MD, PhD; Jeffrey L. Bennett, MD, PhD; Eoin P. Flanagan, MB, BCh

View more